BioSpace News Archive

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that the Company will host a conference call and live audio webcast on Wednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020. Conference Call Information: Interested participants and investors may access the conference call by

BehaVR , a leading innovator of virtual reality digital wellness and digital therapeutics experiences, today announced that it has begun a new partnership aimed at leveraging virtual reality experienc

B. Braun Medical Inc. and Kerma Medical Products, Inc. announced a collaboration to improve the development and delivery of healthcare products and services, with an emphasis on veteran, minority and other underserved communities.

United Imaging now preferred medical imaging partner for MyoStrain® and its unique diagnostic cardiac test.

Comprehensive clinical resource platform increases the availability and quality of patient care through evidence-based decision support across the medical device supply chain

Personalized Stem Cells, Inc, a human adipose-derived stem cell company, has announced that enrollment is officially complete for their FDA approved stem cell clinical trial for treatment of knee osteoarthritis.

ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor

MannKind Corporation reported financial results for the quarter and six months ended June 30, 2020.

Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $15.5 million in second quarter 2020

- University of California Irvine is the first California site participating in Celularity’s CYNK-001-COVID-19 clinical trial NCT04365101 using Celularity’s investigational immunotherapy to treat adults who tested COVID-19 positive in underserved and disproportionately affected populations. - CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells. [05-Augu